CP-105,696
CAS: 158081-99-3
Ref. 3D-IGA08199
| 5mg | 403.00 € | ||
| 10mg | 574.00 € | ||
| 25mg | 1,025.00 € | ||
| 50mg | 1,543.00 € | ||
| 100mg | 2,468.00 € |
Product Information
- 1-[(3S,4R)-3-([1,1′-Biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]cyclopentanecarboxylic acid
- Cp 105696
- Cyclopentanecarboxylic acid, 1-[(3S,4R)-3-([1,1′-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-
- Cyclopentanecarboxylic acid, 1-[3-([1,1′-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-, (3S-trans)-
- Cyclopentanecarboxylicacid, 1-[3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-,(3S-trans)-
- Pfizer 105696
CP-105,696 is a monoclonal antibody that binds to the chemoattractant protein (CXCL12) and blocks its activity. CP-105,696 has been shown to inhibit the growth of cancer cells in vitro and in vivo by binding to CXCR4, a receptor for CXCL12. It is also used for the treatment of inflammatory bowel disease and other autoimmune diseases. CP-105,696 inhibits inflammatory responses by blocking the release of proinflammatory cytokines IL-1β and TNFα from activated macrophages. The drug binds to a region on the chemokine that is involved in cell signaling, preventing it from interacting with its receptor. CP-105,696 also inhibits angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
Chemical properties
Technical inquiry about: 3D-IGA08199 CP-105,696
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
